Novacyt continues to advance the science behind diagnostic testing
19 Sep 2021
Novacyt will be showcasing its most recent developments at this year’s Lab Innovations – with innovation fuelled by the growing needs of the COVID-19 pandemic.
Building on years of expertise in clinical diagnostics, the Novacyt Group has been keeping pace with urgent testing requirements for the COVID original virus and its emerging variants.
The company sees its bioinformatics surveillance ability, in-house skills to run clinical trials, and ability to rapidly scale regulatory and manufacturing capabilities according to demand as key strengths that set it apart in diagnostic breakthroughs.
Stand E72 at Lab Innovations will used to highlight the Novacyt’s most recent additions to its product portfolio of advanced molecular and protein detection technologies designed to provide patient-led focus and high-quality innovations that advance the science behind diagnostics in microbiology, haematology and serology testing
To celebrate its return visit to Lab Innovations, Novacyt will be offering 10% discount on testing kits and 20% discount on an instrument for any registered Lab Innovations visitor to the Novacyt E72 booth.